Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Clinical Trials in France / NCT06830629
Recruiting Phase 2

A Phase 2 Study of MZE829 in Adults With APOL1 Kidney Disease

NCT06830629 · tracked via the Priya Life Science France tracker
Sponsor
Maze Therapeutics
Phase
Phase 2
Started
2025-02-05
Last updated
2026-07-27

Condition(s) studied

Proteinuric Kidney Disease

Investigational drug(s) / intervention(s)

MZE829

MZE829: Capsules for oral administration

Study summary

The purpose of this study is to evaluate the safety, tolerability, and effect on Albuminuria of MZE829 in Adults with APOL1 Kidney Disease.

Eligibility

Sex
ALL
Min age
18 Years
Max age
68 Years
Healthy volunteers
No
Key Inclusion Criteria: * APOL1 high risk genotype of G1/G1, G2/G2, or G1/G2 * Chronic kidney disease with persistent albuminuria Key Exclusion Criteria: * Organ or bone marrow transplantation * History of active cancer within past 2 years, except for treated non-melanoma skin cancer, stage 0 cervical cancer, or stage 1 prostate cancer * Conditions that may alter drug absorption, e.g., history of bariatric surgery * Type I diabetes * Pregnant or currently nursing Other inclusion/exclusion criteria defined in protocol apply.

Primary outcome measure(s)

  • Safety and tolerability as assessed by incidence of adverse events (AEs) — Baseline to Week 12

Trial sites (79)

FacilityCityRegionStatus
Research Site Decatur Alabama Recruiting
Research Site Huntsville Alabama Recruiting
Research Site Montgomery Alabama Recruiting
Research Site Montgomery Alabama Recruiting
Research Site Bloomfield Connecticut Recruiting
Research Site Washington D.C. District of Columbia Recruiting
Research Site Atlantis Florida Recruiting
Research Site Brandon Florida Recruiting
Research Site Hollywood Florida Recruiting
Research Site Melbourne Florida Recruiting
Research Site Orlando Florida Recruiting
Research Site Atlanta Georgia Recruiting
Research Site College Park Georgia Recruiting
Research Site Cordele Georgia Recruiting
Research Site Macon Georgia Recruiting
Research Site Riverdale Georgia Recruiting
Research Site Riverdale Georgia Recruiting
Research Site Savannah Georgia Recruiting
Research Site Snellville Georgia Recruiting
Research Site Chicago Illinois Recruiting
Research Site Chicago Illinois Recruiting
Research Site Evanston Illinois Recruiting
Research Site Kansas City Kansas Recruiting
Research Site Bowling Green Kentucky Recruiting
Research Site Louisville Kentucky Recruiting
Research Site Arnold Maryland Recruiting
Research Site Lutherville Maryland Recruiting
Research Site Oxon Hill Maryland Recruiting
Research Site Dearborn Michigan Recruiting
Research Site Flint Michigan Recruiting
Research Site Pontiac Michigan Recruiting
Research Site Saint Joseph Michigan Recruiting
Research Site Minneapolis Minnesota Recruiting
Research Site Tupelo Mississippi Recruiting
Research Site City of Saint Peters Missouri Recruiting
Research Site St Louis Missouri Recruiting
Research Site Las Vegas Nevada Recruiting
Research Site Jersey City New Jersey Recruiting
Research Site Buffalo New York Recruiting
Research Site Laurelton New York Recruiting

+ 39 more sites — see the full list on the official registry below.

More Maze Therapeutics trials in France

A Study of MZE782 in Adults With PKU Recruiting

Other trials for the same condition

Phase 2/3 Adaptive Study of VX-147 in Adult and Pediatric Participants With APOL1-Mediated Proteinuric Kidney Disease Active, not recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06830629 on ClinicalTrials.gov ↗ ← All trials in France